CN
EN
TC
About Us
About Us
Management Team
Our Culture
Our History
Business Conduct and Ethics
ESG
Award and Recognition
Media Center
Platform
Peptide CRDMO Platform
Oligonucleotide CDMO Platform
News
Press Release
Events
Careers
Talent Outlook
China Opportunities
Contact Us
Investors
Listing Documents
Financial Reports
Announcements & Notices
Corporate Governance
Press Release
Events
2026-07-31
Medtide Inc. Subsidiary Chinese Peptide Company Announces Successful Completion of U.S. FDA Pre-License Inspection (PLI) for Hepcludex® API, Establishing a Proven Track Record Under the Stringent BLA Pathway
More
2026-07-16
MEDTIDE Executive Closed-Door Forum 2026 Concludes Successfully: Top-Level Dialogue Reshapes the Peptide Industry Landscape
More
2026-06-30
Honored Milestone: Medtide Inc. Named in the "Top 20 Pharmaceutical CDMO Enterprises 2026"
More
MEDTIDE Inc. Earns EcoVadis Rating for Sustainability Commitments and Performance
More
Chinese Peptide Company, Subsidiary of Medtide Inc.: Tirzepatide API Successfully Secures US FDA DMF Filing, Fully Empowering the Global Weight Loss and Metabolism Arena
More
Good News | Medtide Inc.’s Subsidiary Chinese Peptide Company Sees Triptorelin Pamoate API Accepted for CDE Registration, Adding a New Product to Its Peptide Hormone Regulatory Portfolio
More
Medtide Inc. Awarded “Leading Enterprise” in the 2026 Forbes China Industry Development Pioneers Selection
More
Prev
1
2
3
Next
